These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30176869)

  • 1. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014-2017).
    Musser ML; Taikowski KL; Johannes CM; Bergman PJ
    BMC Vet Res; 2018 Sep; 14(1):272. PubMed ID: 30176869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
    Berger EP; Johannes CM; Jergens AE; Allenspach K; Powers BE; Du Y; Mochel JP; Fox LE; Musser ML
    J Vet Intern Med; 2018 Nov; 32(6):2045-2053. PubMed ID: 30307656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma.
    Musser ML; Johannes CM
    BMC Vet Res; 2021 Aug; 17(1):269. PubMed ID: 34380474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018.
    Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE
    Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma.
    Kim C; Matsuyama A; Mutsaers AJ; Woods JP
    Can Vet J; 2017 Oct; 58(10):1059-1064. PubMed ID: 28966355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective evaluation of toceranib phosphate (Palladia) in the treatment of canine carcinomatosis and mesothelioma.
    Hicks KA; Leeper HJ; Curran KM
    Vet Comp Oncol; 2024 Jun; 22(2):245-254. PubMed ID: 38622074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
    Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs.
    Heaton CM; Fernandes AFA; Jark PC; Pan X
    J Vet Intern Med; 2020 Mar; 34(2):873-881. PubMed ID: 31977135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
    Wouda RM; Hocker SE; Higginbotham ML
    Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
    Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
    BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toceranib phosphate in the treatment of canine thyroid carcinoma: 42 cases (2009-2018).
    Sheppard-Olivares S; Bello NM; Wood E; Szivek A; Biller B; Hocker S; Wouda RM
    Vet Comp Oncol; 2020 Dec; 18(4):519-527. PubMed ID: 32012432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.
    Pan X; Tsimbas K; Kurzman ID; Vail DM
    Vet Comp Oncol; 2016 Jun; 14(2):202-9. PubMed ID: 24735385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis.
    Tani H; Miyamoto R; Noguchi S; Kurita S; Nagashima T; Michishita M; Yayoshi N; Tamura K; Bonkobara M
    BMC Vet Res; 2021 Apr; 17(1):147. PubMed ID: 33827546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.
    Leblanc AK; Miller AN; Galyon GD; Moyers TD; Long MJ; Stuckey AC; Wall JS; Morandi F
    Vet Radiol Ultrasound; 2012; 53(3):348-57. PubMed ID: 22360684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.
    Laver T; London CA; Vail DM; Biller BJ; Coy J; Thamm DH
    Vet Comp Oncol; 2018 Mar; 16(1):E23-E29. PubMed ID: 28621057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.
    London C; Mathie T; Stingle N; Clifford C; Haney S; Klein MK; Beaver L; Vickery K; Vail DM; Hershey B; Ettinger S; Vaughan A; Alvarez F; Hillman L; Kiselow M; Thamm D; Higginbotham ML; Gauthier M; Krick E; Phillips B; Ladue T; Jones P; Bryan J; Gill V; Novasad A; Fulton L; Carreras J; McNeill C; Henry C; Gillings S
    Vet Comp Oncol; 2012 Sep; 10(3):194-205. PubMed ID: 22236194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of palliative therapy, alone or in combination with toceranib phosphate, in dogs diagnosed with metastatic or recurrent beta-cell neoplasia.
    Alonso-Miguel D; García-San José P; González Sanz S; Clarés Moral I; Pérez-Alenza MD
    N Z Vet J; 2021 Jul; 69(4):234-239. PubMed ID: 33944682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Survival and Glycemic Control with Toceranib Phosphate and Prednisone for a Metastatic Canine Insulinoma.
    Flesner BK; Fletcher JM; Smithee T; Boudreaux B
    J Am Anim Hosp Assoc; 2019; 55(1):e55105. PubMed ID: 30427714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
    Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
    BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.
    Burton JH; Venable RO; Vail DM; Williams LE; Clifford CA; Axiak-Bechtel SM; Avery AC; Thamm DH
    J Vet Intern Med; 2015; 29(4):1098-104. PubMed ID: 26119008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.